About the Company
Plato BioPharma, Inc. (PBI) is located between Denver & Boulder at the base of Colorado’s front range of the Rocky Mountains. PBI was founded in late 2009 by Dr. Craig Plato with the intent of building a world class CRO for in vivo pre-clinical drug discovery. With Dr. Plato’s extensive drug discovery experience and his recognized expertise in cardiovascular, renal and pulmonary pathophysiology, PBI delivers:
♦ high-end preclinical models of human disease,
♦ pharmacological evaluation of early and late stage discovery and development compounds, and
♦ proof of concept testing in support of target discovery and validation by delivering precise and consistent functional evaluations of critical organ systems
Prior to the founding of PBI, Dr. Plato was the director of in vivo pharmacology for Myogen, Inc. in Colorado. In 2006, Gilead Sciences, Inc. acquired Myogen to diversify beyond their existing antiviral therapeutic specialization and enter into the cardiovascular and renal disease areas. Dr. Plato continued to grow and expand the Colorado in vivo laboratory under Gilead’s corporate umbrella. In 2009, Gilead acquired CV Therapeutics (CVT) (another cardiovascular biotech company) and announced their plans to both outsource in vivo testing as well as to consolidate their cardiovascular operations to CVT’s California headquarters.
With the closing of the Colorado facility, Dr. Plato acquired a significant amount of Gilead’s laboratory equipment and leased the newly opened Gilead laboratory facility as well. In essence, Dr. Plato was able to continue the laboratory he designed and built for Gilead, with a new name on the door – Plato BioPharma.
A Successful and Experienced Team
PBI’s current team is comprised of many former Myogen and Gilead employees whom have worked with Dr. Plato for many years. This team was the discovery pharmacology engine within cardiovascular, renal and pulmonary therapeutic areas for both Gilead Sciences as well as Novartis via their collaborative heart failure drug discovery partnership with Myogen. The PBI team brought multiple discovery projects to first-in-man over a six year span and enabled the approval of an FDA orphan drug filing. Overall, the PBI team has over 70 years of combined experience in the critical aspects of PBI’s integrative discovery research approach. Additionally, Dr. Plato has assembled an esteemed strategic advisory board for the company.